Granisetron was more Effective than Ondansetron as Antiemetic in Ovarian Cancer Patients: a Randomized Controlled Trial
Kusumanto A., Prawitasari S., Reza H.
Abstract
Objective: To determine the effectiveness of intravenous injection of granisetron compared to ondansetron in preventing nausea and vomiting, we used the MASCC Antiemesis Tool (MAT) in ovarian cancer patients undergoing paclitaxel-carboplatin chemotherapy Methods: This study was conducted as a double-blind, randomized controlled trial. The treatment group received 1 mg of granisetron, whereas the control group received 8 mg of ondansetron intravenously. Nausea and vomiting were assessed using the MAT scale at 12 hours, 24 hours, and 48 hours after chemotherapy. The differences in MAT scores between the groups were analyzed using the Mann-Whitney test. Results: A total of 60 participants were enrolled in this study. The results indicated that the MAT score at the 12-hour mark significantly differed from the 24-hour and 48-hour MAT scores (p = 0.00, p = 0.00). The MAT scores in the granisetron group at 12 hours, 24 hours, and 48 hours were statistically lower compared to the ondansetron group (p = 0.00, p = 0.00, p = 0.00). Conclusions: In conclusion, intravenous granisetron proved to be more effective than intravenous ondansetron in preventing nausea and vomiting among patients with ovarian cancer undergoing paclitaxel-carboplatin chemotherapy.
Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study
Barduagni M., Cognetti F., Fabi A., Giampaolo M., Lauro S., Marinis F., Mauri M., Narduzzi C., Pacetti U., Paoloni F., Portalone L., Tonini G.
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
Fujiwara K., Katakami N., Kitao A., Matsumoto K., Minami H., Morita S., Negoro S., Shibata N., Tanioka M., Tanioka M., Yamaguchi S.
Efficacy and Tolerability of Granisetron versus Ondansetron in the Prevention of Chemotherapy-Induced Nausea and Vomiting among Cancer Patients at Kenyatta
Muhire I.
No Title
Comparison of the antiemetic effectiveness between Granisetron and Dexamethasone with Ondansetron and Dexamethasone in Acute-Phase Chemotherapy Patients
Arfilanil R. F., Supraptil B., Susilo D. H.
Cancer chemotherapy-induced nausea and vomiting: Role of mediators, development of drugs and treatment methods
Mahesh R., Pandi P.V., Venkatesha Perumal R.
Validation and Psychometric Assessment of a Short Clinical Scale to Measure Chemotherapy-Induced Nausea and Vomiting: The MASCC Antiemesis Tool
Clements C., Coventry P.A., Eaby B., Gralla R.J., Molassiotis A., Rittenberg C., Stricker C.T., Velders L.
Retrospective analysis of chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer patients treated with antiemetics
Goil T., Kimura Y., Nakazawa T.
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Colombo N., Landoni F., McMeekin D. S., Morabito A., Sessa C.
Ovarian cancer statistics, 2018
DeSantis C.E., Gaudet M.M., Jemal A., Miller K.D., Runowicz C.D., Samimi G., Siegel R.L., Torre L.A., Trabert B.
Ahangari G., Norioun H.
Neuroscience
